Background/Aims: The in vivo metabolic profile of a benzopyridooxathiazepine (BPT) derivative, a potent tubulin polymerization inhibitor with a promising in vitro activity, was investigated. Methods: The quantification of the BPT derivative and the identification of metabolites in the plasma of Wistar rats after i.p. and oral administration of 10 mg/kg were performed by the HPLC-mass spectrometry method. Results: Following a single i.p. dose of the BPT derivative, the plasma concentrations showed a biexponential decay (with a rapid decline) followed by a slow decay with a terminal half-life of 77.90 min. The area under the concentration-time curve from time 0 to infinity (AUC0-) was 18.90 µg/ml·min. After oral administration, the plasmatic concentrations reached a peak of 0.06 μg/ml at 35 min and then decayed with a half-life of 108 min. The AUC0- was 10.25 µg/ml·min, representing 54.2% of the relative bioavailability. The compound was well distributed in the body, and its elimination seemed to be fast, regardless of the administration route. The major metabolic pathways were demethylation and hydroxylation reactions, both followed by conjugation with glucuronic acid. Conclusion: In rats, the BPT derivative is well distributed and undergoes extensive metabolism, leading to several metabolites. With promising in vitro activity and very good oral bioavailability, this compound seems to be an attractive candidate for further development as an anticancer agent.

1.
Schiff PB, Fant J, Horwitz SB: Promotion of microtubule assembly in vitro by taxol. Nature 1979;277:665-667.
2.
Jordan A, Hadfield JA, Lawrence NJ, McGown AT: Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle. Med Res Rev 1998;18:259-296.
3.
Li Q, Sham HL, Rosenberg SH: Chapter 14: antimitotic agents. Annu Rep Med Chem 1999;34:139-148.
4.
Nam NH: Combretastatin A-4 analogues as antimitotic antitumor agents. Curr Med Chem 2003;10:1697-1722.
5.
Yoshimatsu K, Yamaguchi A, Yoshino H, Koyanagi N, Kitoh K: Mechanism of action of E7010, an orally active sulfonamide antitumor agent: inhibition of mitosis by binding to the colchicine site of tubulin. Cancer Res 1997;57:3208-3213.
6.
Pedrini FS, Chiaradia LD, Licinio MA, de Moraes AC, Curta JC, Costa A, Mascarello A, Creczinsky-Pasa TB, Nunes RJ, Yunes RA, Santos-Silva MC: Induction of apoptosis and cell cycle arrest in L-1210 murine lymphoblastic leukaemia cells by (2E)-3-(2-naphthyl)-1-(3′-methoxy-4′-hydroxy-phenyl)-2-propen-1-one. J Pharm Pharmacol 2010;62:1128-1136.
7.
Jiang C, Yang L, Wu WT, Guo QL, You QD: CPUYJ039, a newly synthesized benzimidazole-based compound, is proved to be a novel inducer of apoptosis in HCT116 cells with potent KSP inhibitory activity. J Pharm Pharmacol 2011;63:1462-1469.
8.
Nien CY, Chen YC, Kuo CC, Hsieh HP, Chang CY, Wu JS, Wu SY, Liou JP, Chang JY: 5-Amino-2-aroylquinolines as highly potent tubulin polymerization inhibitors. J Med Chem 2010;53:2309-2313.
9.
Li Q, Sham HL: Discovery and development of antimitotic agents that inhibit tubulin polymerisation for the treatment of cancer. Expert Opin Ther Pat 2002;12:1663-1702.
10.
Hadfield JA, Ducki S, Hirst N, McGown AT: Tubulin and microtubules as targets for anticancer drugs. Prog Cell Cycle Res 2003;5:309-325.
11.
Lee WH, Liu HE, Chang JY, Liou JP, Huang HM: MPT0B169, a new tubulin inhibitor, inhibits cell growth and induces G2/M arrest in nonresistant and paclitaxel-resistant cancer cells. Pharmacology 2013;92:90-98.
12.
Gallet S, Flouquet N, Carato P, Pfeiffer B, Renard P, Léonce S, Pierre A, Berthelot P, Lebegue N: Benzopyridooxathiazepine derivatives as novel potent antimitotic agents. Bioorg Med Chem 2009;17:1132-1138.
13.
Togami K, Tosaki Y, Chono S, Morimoto K, Hayasaka M, Tada H: Enantioselective uptake of fexofenadine by Caco-2 cells as model intestinal epithelial cells. J Pharm Pharmacol 2013;65:22-29.
14.
Lecoeur M, Vérones V, Vaccher C, Bonte JP, Lebegue N, Goossens JF: Structural elucidation of degradation products of a benzopyridooxathiazepine under stress conditions using electrospray orbitrap mass spectrometry: study of degradation kinetic. Eur J Pharm Sci 2012;45:559-569.
15.
Verones V, Flouquet N, Lecoeur M, Lemoine A, Farce A, Baldeyrou B, Mahieu C, Wattez N, Lansiaux A, Goossens JF, Berthelot P, Lebegue N: Synthesis, antiproliferative activity and tubulin targeting effect of acridinone and dioxophenothiazine derivatives. Eur J Med Chem 2013;59:39-47.
16.
Naritomi Y, Terashita S, Kagayama A, Sugiyama Y: Utility of hepatocytes in predicting drug metabolism: comparison of hepatic intrinsic clearance in rats and humans in vivo and in vitro. Drug Metab Dispos 2003;31:580-588.
17.
Clarke SE, Jeffrey P: Utility of metabolic stability screening: comparison of in vitro and in vivo clearance. Xenobiotica 2001;31:591-598.
18.
Bourdon F, Lecoeur M, Verones V, Vaccher C, Lebègue N, Dine T, Kambia N, Goossens JF: In vitro pharmacokinetic profile of a benzopyridooxathiazepine derivative using rat microsomes and hepatocytes: identification of phases I and II metabolites. J Pharm Biomed Anal 2013;80:69-78.
19.
Yamaoka K, Nakagawa T, Uno T: Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm 1978;6:165-175.
20.
Davies B, Morris T: Physiological parameters in laboratory animals and humans. Pharm Res 1993;10:1093-1095.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.